Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Legend Biotech (LEGN) EBITDA Margin (2019 - 2025)

Legend Biotech filings provide 7 years of EBITDA Margin readings, the most recent being 6.43% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 3609.0% to 6.43% in Q4 2025 year-over-year; TTM through Dec 2025 was 8.05%, a 1365.0% increase, with the full-year FY2025 number at 13.27%, up 3607.0% from a year prior.
  • EBITDA Margin hit 6.43% in Q4 2025 for Legend Biotech, down from 14.9% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 596.51% in Q2 2022 to a low of 97962.57% in Q1 2021.
  • Median EBITDA Margin over the past 5 years was 132.38% (2023), compared with a mean of 4709.4%.
  • Biggest five-year swings in EBITDA Margin: tumbled -9845134bps in 2021 and later surged 9820825bps in 2022.
  • Legend Biotech's EBITDA Margin stood at 230.36% in 2021, then skyrocketed by 72bps to 395.35% in 2022, then plummeted by -85bps to 57.62% in 2023, then tumbled by -174bps to 42.52% in 2024, then surged by 85bps to 6.43% in 2025.
  • The last three reported values for EBITDA Margin were 6.43% (Q4 2025), 14.9% (Q3 2025), and 0.46% (Q2 2025) per Business Quant data.